In a murine C‐protein‐induced myositis (CIM) model, treatment with CTLA4‐Ig or anti‐CD80/86 antibodies effectively suppressed myositis, suggesting its potential therapeutic feasibility for myositis [37]. This evidence concerns the gene CTLA4 and myositis disease.